中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
13期
54-55,56
,共3页
周文莉%李红刚%朱本淑%王旭
週文莉%李紅剛%硃本淑%王旭
주문리%리홍강%주본숙%왕욱
药品不良反应%分析%合理用药
藥品不良反應%分析%閤理用藥
약품불량반응%분석%합리용약
adverse drug reactions%analysis%rational drug use
目的:探讨药品不良反应(ADR)的发生特点,促进临床合理用药。方法选取医院2012至2013年收集的70例ADR病例,对性别、年龄、药物种类、涉及的具体药品、临床表现等进行回顾性统计分析。结果70例ADR报告中,性别无明显差异;年龄以41~60岁和18岁以下发生率最高;药物种类以营养药、中药制剂、抗菌药物3大类为主,涉及的具体药物品种以哌拉西林他唑巴坦、注射用脂溶性维生素I、参芎葡萄糖注射液为主;临床表现以过敏性皮疹最多见,过敏性休克和重症药疹最严重。结论临床应着重加强对营养药、中药制剂、抗菌药物以及联合用药的监管,以减少或避免ADR发生。
目的:探討藥品不良反應(ADR)的髮生特點,促進臨床閤理用藥。方法選取醫院2012至2013年收集的70例ADR病例,對性彆、年齡、藥物種類、涉及的具體藥品、臨床錶現等進行迴顧性統計分析。結果70例ADR報告中,性彆無明顯差異;年齡以41~60歲和18歲以下髮生率最高;藥物種類以營養藥、中藥製劑、抗菌藥物3大類為主,涉及的具體藥物品種以哌拉西林他唑巴坦、註射用脂溶性維生素I、參芎葡萄糖註射液為主;臨床錶現以過敏性皮疹最多見,過敏性休剋和重癥藥疹最嚴重。結論臨床應著重加彊對營養藥、中藥製劑、抗菌藥物以及聯閤用藥的鑑管,以減少或避免ADR髮生。
목적:탐토약품불량반응(ADR)적발생특점,촉진림상합리용약。방법선취의원2012지2013년수집적70례ADR병례,대성별、년령、약물충류、섭급적구체약품、림상표현등진행회고성통계분석。결과70례ADR보고중,성별무명현차이;년령이41~60세화18세이하발생솔최고;약물충류이영양약、중약제제、항균약물3대류위주,섭급적구체약물품충이고랍서림타서파탄、주사용지용성유생소I、삼궁포도당주사액위주;림상표현이과민성피진최다견,과민성휴극화중증약진최엄중。결론림상응착중가강대영양약、중약제제、항균약물이급연합용약적감관,이감소혹피면ADR발생。
Objective To study the occurrence characteristics of adverse drug reactions ( ADR ) to promote rational drug use. Methods 70 cases of ADR collected in our hospital during 2012-2013 were selected and performed the etrospective analysis on the sex, age, drug type, involved concrete drugs, clinical manifestations, etc. Results Among 70 cases of ADR, gender had no significant difference, the age of 41-60 years old and below 18 years old had the highest incidence rate;the drug types were dominated by three categories of the nutritional drugs, Chinese medicine preparations and antibacterial dugs, the involved concrete drugs were mainly piperacillin and tazobactam, Fat-Soluble Vitamins I for Injection and Shenxiong Glucose Injection;the most of clinical manifestations were allergic skin rash, anaphylactic shock and severe drug rash were most serious. Conclusion Clinic should focus on strengthening the supervision on nutritional drugs, Chinese medicine preparations and antibacterial drugs, as well as the supervision on the combined medication to reduce or avoid the occurrence of ADR.